US SEC Trading Suspension Halt Orders — May 04, 2026

Closing bid price below $1.00 for 30 consecutive business days (March 18-April 29, 2026), triggering Nasdaq Rule 5550(a)(2) non-compliance

180-day compliance window until October 27, 2026, with potential reverse stock split; historical reverse splits often fail to sustain price (cross-ref Jaguar)

Negative sentiment (explicitly stated), high materiality 9/10, no forward-looking financial guidance or positive operational metrics

Post 1-for-35 reverse stock split (April 30, 2026), publicly held shares at 401,226 vs required 500,000 (Nasdaq Rule 5550(a)(4)), additional delisting basis

Ongoing bid price non-compliance alongside low share count, no assurance of regaining $1.00 for 10 consecutive days per Rule 5810(c)(3)(A)

Nasdaq Hearings Panel to review, must respond by May 8, 2026; reverse split QoQ failed to resolve deficiencies

Negative sentiment, materiality 10/10 (vs Hoth 9/10), indicating relatively worse compliance outlook

Both on Nasdaq Capital Market with bid price issues; Jaguar's recent reverse split underperformance signals Hoth risk if similar action taken

No insider buying or positive capital allocation (e.g., buybacks/dividends) noted amid deficiency; zero enriched insider activity

No forward-looking guidance beats or operational improvements post-split; enriched forward data limited to uncertain compliance

Zero YoY/QoQ financial growth or margin expansion; pure regulatory decline trend over 30-day periods

No scheduled positive events like earnings; only compliance deadlines, lacking bullish catalysts

Bid price < $1 for 30 days, 180-day cure period ends October 27, 2026; failure risks immediate delisting review

Intends to monitor and potentially implement reverse split, but Jaguar's 1:35 split failed, compressing shares further

Only 401,226 publicly held shares post-split vs 500,000 req, providing additional delisting basis for Hearings Panel

Must respond by May 8, 2026; panel considers bid price + share count failures under Rule 5810(c)(3)(A)

Absence of enriched positive trends (revenue/margins/ROE) or capital allocation (dividends/buybacks) amid compliance stress

QoQ post-April 30, 2026 split worsened position vs pre-split expectations, no compliance assurance

Continued non-compliance risks trading suspension; both trade under 'HOTH' but delisting imminent without cure

Both show 30+ day declining bid price periods, no YoY recovery signals in enriched data

Zero enriched insider transactions/pledges/holdings indicating conviction; management silence on selling/buying

Materiality 10/10 vs Hoth 9/10, post-split share decline highlights deteriorating position

Potential to achieve $1.00 bid for 10 days within 180-day window (to Oct 27, 2026); second period possible if other rules met

If implemented successfully (unlike Jaguar), could spark short-term squeeze; monitor bid price rebound

May 8, 2026 deadline to present compliance plan; positive response could extend listing, undervalued if successful

Working toward $1.00 for 10 days; post-split low float (401k shares) amplifies upside if compliant

High delisting risk (9/10 materiality) offers short opportunity pre-October deadline, no financial positives

Failed reverse split + hearings create 10/10 risk premium; trade suspension likely without cure

Jaguar's 401k shares post-split vs Hoth's potential; relative outperformance if one cures first

Delisting could enable OTC trading arbitrage for nimble investors; watch for volume spikes on notices

2/2 filings show bid price < $1 for 30 days, with reverse splits (Jaguar 1:35) failing to cure; implies sector-wide small-cap distress

Jaguar QoQ post-split share count declined to 401k vs 500k req; Hoth contemplates similar, historical pattern erodes shareholder value

Jaguar at 401,226 shares highlights post-split vulnerability; cross-company avg float deficiency ~20% below req

Hoth 180-day (Oct 27), Jaguar immediate hearings (May 8); no enriched financial trends to support recovery

Zero insider activity, capital allocation, or YoY growth across filings; pure regulatory negative sentiment (100% negative)

Both on Nasdaq Capital Market; Rule 5550/5810 violations cluster, signaling portfolio rotation out of micro-cap biotechs

Monitor daily closing bid for 10 consecutive days >= $1.00; deadline October 27, 2026

Watch for 8-K on split plans, given intent; potential within 180 days

Written response due May 8, 2026; key for delisting decision

Track efforts to increase to 500,000 shares post 1:35 split; ongoing

Daily monitoring for $1.00 over 10 days per Rule 5810(c)(3)(A); no timeline assured

Nasdaq panel decisions post-May 8 (Jaguar) and Oct 27 (Hoth if fail); potential suspensions

Watch for new Form 4 filings on buys/sells amid compliance stress; none currently

If delisted, monitor OTCQB/OTC Pink transitions for trading halts or volume